|Mr. Dayton Misfeldt||Interim CEO & Director||150k||N/A||1974|
|Mr. William P. Quinn||Sr. VP of Fin. & Corp. Devel. and CFO||449.63k||N/A||1971|
|Mr. Gene C. Jamieson||VP of Technical Operations||N/A||N/A||N/A|
|Dr. Judith A. Fox||Chief Scientific Officer and Exec. VP of R&D||N/A||N/A||N/A|
|Mr. Stephen Nava||VP of Quality Assurance, Compliance & Regulatory Affairs||N/A||N/A||N/A|
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Sunesis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.